乳腺癌新辅助化疗后原发灶临床完全缓解对腋淋巴结转阴的预测作用

目的 判断腋窝淋巴结阳性乳腺癌新辅助化疗(neoadjuvant chemotherapy,NAC)后原发灶临床完全缓解能否预测腋窝淋巴结病理转阴.方法 2016年10月 ～2019年10月收治的乳腺癌病人95例,淋巴结穿刺均阳性,临床分期T1-3,N1-2期,且均完成NAC后有腋窝淋巴结清扫(axillary lym...     

多西他赛+卡铂联合曲妥珠单抗方案对早期人表皮生长因子受体2阳性乳腺癌的新辅助治疗效果

目的探讨多西他赛+卡铂联合曲妥珠单抗(TCH)方案对早期人表皮生长因子受体2(HER2)阳性乳腺癌的新辅助治疗效果。方法回顾性分析2013年1月至2018年12月北京大学第一医院乳腺疾病中心经治的522例早期HER2阳性乳腺癌患者的临床资料,占同期收治早期浸润性乳腺癌患者的21.80%(522/2 394)。其中113例接受TCH方案进行新辅助治疗,年龄[M(QR)]52(13)岁(范围:23~69岁)。记录TCH方案新辅助治疗后病理完全缓解(pCR,ypT0N0M0期)的例数,采用Miller-Payne标准进行病理学评价。采用Kaplan-Meier法计算无病生存率和总体生存率,采用Log-rank检验比较组间生存差异。结果接受曲妥珠单抗规范治疗患者(294例)的无病生存率优于未规范治疗患者(177例)(84.4%比72.4%,χ²=4.095,P=0.046)。发生3~4级不良反应的患者占全部患者的15.9%(18/113),包括3~4级中性粒细胞减少12例,腹泻6例。31例患者获得pCR(ypT0N0M0),pCR率为27.4%(31/113)。pCR患者与非pCR患者的无病生存率和总体生存率无差异(91.8%比85.0%,92.5%比90.5%,P值均>0.05)。病理学评价为G4~5的患者无病生存率优于G1~3患者(89.6%比81.5%,χ²=5.340,P=0.021),而总体生存率的差异无统计学意义(91.4%比89.1%,χ²=1.008,P=0.315)。结论早期HER2阳性乳腺癌采用TCH方案行新辅助治疗的效果较好,新辅助治疗后病理学评价为G4~5的患者的无病生存率更高。     

甲状腺髓样癌临床诊疗方案分析

目的:探讨影响甲状腺髓样癌（medullary thyroid carcinoma,MTC）治疗方案制订与转归的关键要素。方法:回顾性分析2007年4月至2020年3月湖南省人民医院乳甲外科收治的23例MTC患者病例资料、典型病例的临床特点及生存随访结果,结合ATA等指南对MTC治疗方案和转归进行分析。结果:23例MT...     

The use of Nolvadex in the treatment of generic Tamoxifen-associated small joint arthralgia

IntroductionSmall joint arthralgia has been anecdotally reported for many years by women taking generic Tamoxifen (gT). However, it is a symptom that is absent from the side effect profile of the original Tamoxifen preparation Nolvadex. Our aim was to determine the prevalence of arthralgia in Tamoxifen users and to investigate whether it was associated with the excipient profile of the newer, generic formulations of Tamoxifen.MethodsWomen diagnosed with oestrogen receptor positive breast cancer between 2001 and 2005 were eligible. Those with new-onset arthralgia following commencement of gT were entered into a one year double crossover study. Patients were swapped from gT to Nolvadex for 6 months, the response noted, and then swapped back to gT for 6 months.ResultsOf 1020 new breast cancer patients, 918 (90%) were oestrogen receptor (OR) positive and were started on gT as part of their treatment. Of those, a total of 121 (13.2%) suffered with arthralgia. All 121 patients agreed to enter the study and swap treatment to Nolvadex for 6 months 114 patients (94.2%) had resolution of their arthralgia whilst on Nolvadex (p < 0.05).ConclusionOur findings suggest that there is an arthralgia syndrome which is prevalent in women taking generic Tamoxifen preparations. Symptoms are abolished when Nolvadex is used instead of gT. This suggests that the excipient profiles are an important factor. We hypothesise that either the excipient profile of gT induces arthralgia, or an unknown excipient of Nolvadex has a protective effect.     

Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer

We conducted a phase II study using docetaxel and trastuzumab as preoperative systemic treatment for locally advanced HER-2-overexpressing breast cancer (stage IIIB or IIIC) to evaluate the efficacy and safety, and to perform a subset analysis based on tumor biomarkers. Patients received 4 mg/kg trastuzumab on day 1, followed by weekly treatments of 2 mg/kg, in addition to 75 mg/m² docetaxel every 3 weeks for 4 cycles before surgery. The primary end point was clinical response rate measured by MRI or CT. Twenty-five patients were enrolled. The median age was 54 years and median tumor size was 63 mm. The overall clinical response rate was 68% [95% CI: 47–85%] and the pCR rate was 22% [95% CI: 8–44%]. The clinical response and the pCR rates of patients with ER- and PgR- tumors were 79% and 31%, respectively, while they were 55% and 10%, respectively, in the patients with ER+ and/or PgR+ tumors (p = 0.34, p = 0.34, respectively). Cardiac toxicity was well tolerated; there was no evidence of clinical cardiac events in any patient. The combination of docetaxel and trastuzumab produced highly favorable clinical and pathological responses for locally advanced HER-2-overexpressing breast cancer. Subgroup analysis suggests that ER/PgR negative tumors might be associated with pathological response in locally advanced breast cancer.     

基于FNAB的分子检测技术在甲状腺结节诊断中的研究进展

随着各种检测技术的相继问世,甲状腺结节的检出率明显上升。尽管大多数甲状腺结节是良性的,但良恶性病变之间的判定仍然是临床医生面临的挑战。对于所有可疑甲状腺结节患者均应进行颈部超声检查。甲状腺超声可评估结节特征,某些甲状腺结节具有可疑恶性超声征象。然而,这些特征缺乏准确性,无法明确诊断结节的良恶性。目前的指南仍然推荐超声引导细针穿刺活检（FNAB）作为评估甲状腺结节良恶性的首选检查。FNAB是一种经济高效的诊断方法,由于其创伤小,敏感性和特异性较高,可用于术前评估甲状腺结节的性质,已成为临床不可或缺的检查手段之一。近年来国内关于FNAB的报道日益增多,国内外指南关于FNAB指征尚有争议,同时由于其自身存在一定的局限性,FNAB技术的全面实施需要严格把握指征及准确判读穿刺病理结果。FNAB虽然是术前评估甲状腺结节最常用的诊断技术,但仍有灰区结节需要进一步诊断研究。为了制定合理的手术方案及判断预后,指南推荐术前可测定促甲状腺激素（TSH）水平。FNAB作为一个简单且相对无创的技术,但也可产生相应的并发症,FNAB的并发症主要与甲状腺结节的位置、穿刺针的直径、穿刺医师的操作经验等因素相关,严重程度较轻,多呈自限性。对于FNAB无法诊断或意义不明确的非典型病变或滤泡性病变,学者们一直在努力寻找一种新的方法来精确地诊断甲状腺癌。分子生物学方法是目前的最佳选择。分子生物学方法通过检测特定甲状腺肿瘤易感基因的驱动突变来确认甲状腺肿瘤活检的恶性程度,如BRAF和RAS癌基因突变、RET/PTC重排和TERT突变检测,从而提高术前诊断效率。甲状腺乳头状癌最常见的转移部位是局部淋巴结,虽然FNAB对异常淋巴结有诊断价值,但小或囊性淋巴结可能由于缺乏肿瘤细胞而无法诊断。检测可疑颈部淋巴结细针穿刺活检冲洗液中甲状腺球蛋白含量可作为细胞学诊断的辅助手段。笔者认为FNAB联合分子生物学的多层次诊断体系可提高术前诊断的精准性,对指导治疗、判断预后具有重要价值。     

经口腔前庭入路腔镜甲状腺癌根治手术的临床体会

［摘要］ 目的 探讨经口腔前庭入路腔镜甲状腺癌根治术临床应用的可行性及安全性。方法 查询我院实施经口腔前庭入路腔镜甲状腺癌根治手术的临床资料,包括一般资料、手术方式、手术时间、出血量、并发症、住院时间、手术转归和术后病理结果等指标,综合分析该术式的可行性及安全性。结果 2016年11月~2018年11月我科共实施经口腔前庭入路腔镜甲状腺癌根治手术36例,其中女性27例,男性9例,中位年龄27岁（22~32岁）;所有患者均成功实施口腔前庭入路甲状腺癌根治手术（甲状腺腺叶及峡部切除+患侧中央区淋巴结清扫术）,无中转病例;平均手术时间150 min（120~180 min）;术中平均出血量35 mL（20~75mL）;术后均无伤口感染、出血、声音嘶哑、饮水呛咳、手足抽搐等并发症发生;1例术中刺穿颏下皮肤,所有病例术后均出现不同程度的口唇和颏下肿胀,术后7天均基本消退;术后病理结果36例均为甲状腺乳头状癌,中央区淋巴结平均数目5.5枚（3~11枚）;术后3个月复查体表及口腔前庭均无疤痕,患者对美容效果满意。结论 选择合适的病例行经口腔前庭入路腔镜甲状腺癌根治术安全可行,在美容效果和中央区淋巴结清扫彻底性上有优势。     

Pseudomonal breast infection

Breast infection and breast sepsis secondary to Pseudomonas aeruginosa is uncommon. We report two cases of pseudomonal breast infection leading to septic shock and abscess formation in women with non-responding breast infection. The management of breast infection is broad-spectrum antibiotics and ultrasound with aspiration of any collection. To treat breast infection effectively, the causative organism must be isolated to enable appropriate antibiotic therapy.     

Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome

Abstract: Inflammatory breast cancer (IBC) represents a rare but aggressive and lethal form of locally advanced breast cancer (LABC) and frequently with HER‐2 neu overexpressed or amplified. We retrospectively identified 16 newly diagnosed HER‐2/neu‐positive IBC patients who were treated with preoperative trastuzumab. We determined the pathological complete response rate (pCR) when trastuzumab was added to preoperative chemotherapy in patients with HER2/neu‐positive IBC. Furthermore, we assessed the expression of CXCR4 in metastatic recurrence sites. Ten patients (62.5%) achieved a pCR. Six patients (37.5%) achieved a partial response. Median follow‐up of all patients was 24.2 months. Four (25%) patients have experienced a progression, of which three were in the brain. Two‐year progression‐free survival was 59.4% (95% CI 35–100). High expression of CXCR4 was detected in the brain metastases. We conclude that in spite of high pCR rates among women with HER‐2/neu‐positive IBC treated with neoadjuvant trastuzumab‐based regimens the outcome remains dismal and brain recurrences are frequent. CXCR4 may represent a novel therapeutic target.